Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Consolidated Water Company Q1 2026 Earnings Call - Services Surge Masks Manufacturing and Retail Slump
Consolidated Water delivered a mixed Q1 2026 report, with total revenue falling 11% year-over-year to $30 million as manufacturing and retail segments struggled. Manufacturing revenue plummeted 76% du...
- Total revenue declined 11% year-over-year to $30 million, driven by sharp contractions in manufacturing and retail segments.
- Manufacturing revenue collapsed 76% to $1.4 million, primarily due to the timing of purchase orders and internal production shifts to the Hawaii desalination project.
- Retail water sales in Grand Cayman fell 10.2% in volume due to significantly wetter weather, though record tourism arrivals provided a partial offset.
- +7 more takeaways
Venture Global Inc Q1 2026 Earnings Call - Massive EBITDA Guidance Raise and CP2 Construction Momentum
Venture Global delivered a powerful Q1 2026 earnings report that redefined its growth trajectory in the LNG sector. The company raised its full-year EBITDA guidance significantly, reflecting strong op...
- Venture Global raised its 2026 EBITDA guidance to $8.2-$8.5 billion, up from the previous range of $5.2-$5.8 billion, driven by higher sales volumes and favorable liquefaction fees.
- The company achieved record Q1 2026 revenue of $4.6 billion, a 58% increase year-over-year, supported by a 111% rise in sales volumes to 481 TBtu.
- CP2 phase II construction is advancing rapidly, with 12 liquefaction trains and three gas turbines already delivered to the site, targeting first LNG in the second half of 2027.
- +7 more takeaways
D-Wave Systems Inc. Q1 2026 Earnings Call - Bookings Surge 2,000% as Dual-Rail Gate Model Roadmap Accelerates
D-Wave Systems reported a massive 1,994% year-over-year increase in first-quarter bookings, reaching $33.4 million, driven by a $20 million system sale to Florida Atlantic University and a landmark $1...
- Bookings skyrocketed 1,994% year-over-year to $33.4 million, with a 149% sequential increase from Q4 2025, signaling a dramatic shift in commercial and academic demand.
- Revenue dropped 81% to $2.9 million, a distortion caused by a $12.6 million system sale in Q1 2025 that did not recur in the current period.
- Remaining performance obligations (RPO) surged 563% to $42.4 million, with 54% expected to be recognized as revenue within the next 12 months.
- +7 more takeaways
Gladstone Land Corporation Q1 2026 Earnings Call - Strong Pistachio Bonus Drives Q1 Profitability Amid Leasing Shifts
Gladstone Land reported a Q1 2026 net loss of $4.3 million, but adjusted FFO rose to $3.1 million, driven by an early $0.50/lb pistachio crop bonus and participation rent upside. Management is activel...
- Adjusted FFO jumped to $3.1 million, up from $2.0 million in Q1 2025, primarily due to an early $0.50/lb pistachio crop bonus payment.
- Management shifted several leases to variable participation structures to capture crop upside, acknowledging fixed-base rent tenants are scarce due to constrained grower capital.
- Q1 net loss was $4.3 million, with a $0.24 per share loss to common shareholders, masking the underlying operational strength from participation rents.
- +7 more takeaways
Innate Pharma Q1 2026 Earnings Call - Lacutamab Phase III Trial Initiation and AstraZeneca Partnership Value
Innate Pharma advanced its three-priority asset strategy in Q1 2026, with lacutamab securing FDA clearance to begin the confirmatory TELLOMAK-3 phase III trial in cutaneous T-cell lymphoma. The compan...
- Innate Pharma received FDA clearance to proceed with the TELLOMAK-3 confirmatory phase III trial for lacutamab in cutaneous T-cell lymphoma, with initiation expected in the second half of 2026.
- The company is actively negotiating non-dilutive financing options for lacutamab, including potential pharma partnerships and royalty-based structures, with confidence to execute a deal before Q3 2026.
- Lacutamab represents a stepwise commercial opportunity, starting with up to EUR 150 million in Sézary syndrome and expanding to over EUR 500 million across Sézary syndrome and mycosis fungoides.
- +7 more takeaways
Beam Global Q1 2026 Earnings Call - Backlog Surges 50% as Revenue Misses, Non-Cash Charges Cloud Picture
Beam Global reported a sharp 51% year-over-year revenue decline in Q1 2026, driven by seasonal headwinds in Europe, delayed EV ARC deployments, and a geopolitical freeze in the Middle East. Gross marg...
- Revenue fell 51% year-over-year to $3.1 million due to order timing delays and seasonal European slowdowns.
- Backlog grew 50% to $9 million, with smart city applications driving over half of the growth.
- Q2 2026 revenue has already exceeded Q1 2026 results, indicating accelerated business momentum.
- +12 more takeaways
SharonAI Q1 2026 Earnings Call - Secures $2.2B in Contracts and Expands Capacity to 100MW
SharonAI’s first quarter as a public company was defined by aggressive contract signings and capacity expansion, transforming its backlog into a $2.2 billion total contracted value (TCV). The company ...
- SharonAI achieved a $2.2 billion total contracted value (TCV) in Q1 2026, driven by a $1.25 billion five-year take-or-pay contract with Indian IT firm ESDS and a $950 million deal with a major Asia-Pacific technology company.
- The company upgraded its data center capacity target to 100 megawatts by early 2027, up from 70 megawatts, supported by secured power allocations from NEXTDC and new assets in New Zealand.
- SharonAI generated a $74 million non-core gain from the sale of its Texas Critical Data Centers joint venture, providing capital to recycle into its core GPU infrastructure business.
- +7 more takeaways
BioCardia Q1 2026 Earnings Call - Japan PMDA Clears Path for Shonin Approval on CardiAMP
BioCardia delivered a quarter defined by regulatory momentum rather than revenue, advancing its CardiAMP cell therapy for ischemic heart failure toward a pivotal regulatory decision in Japan. The comp...
- Japan’s PMDA has formally indicated it will accept BioCardia’s blinded echocardiography data as the basis for a Shonin pre-market application for CardiAMP, potentially bypassing the need for additional Phase 3 trials in Japan.
- The FDA’s Q-Sub meeting confirmed that a pre-market approval (PMA) is the appropriate pathway for U.S. approval of CardiAMP for ischemic heart failure, and the agency encouraged BioCardia to complete the ongoing CardiAMP HF II trial to support the application.
- Blinded echocardiography data from the CardiAMP Heart Failure Trial showed that treated patients did not experience the negative cardiac remodeling (increased heart volumes) seen in control subjects, with statistically significant benefits in a subgroup with elevated biomarkers.
- +7 more takeaways
Banzai Q1 2026 Earnings Call - Debt Paydown and ConnectAndSell Acquisition Anchor Growth Strategy
Banzai reported a flat run-rate revenue of $2.7 million for Q1 2026, down 20% year-over-year due to a one-time CreateStudio revenue event in Q1 2025. The company is executing a disciplined consolidati...
- Q1 2026 revenue came in at $2.7 million, representing a 20% year-over-year decline primarily driven by a one-time CreateStudio revenue event in Q1 2025. On a run-rate basis, revenue remained flat compared to Q4 2025.
- Gross margins held steady at 80.7%, providing a stable foundation despite the top-line contraction. Gross profit decreased 22% year-over-year to $2.2 million.
- The company closed an additional $2.3 million tranche of convertible debt in February as part of its $11 million facility, while also raising $3.3 million in equity to strengthen the balance sheet.
- +9 more takeaways
Lument Finance Trust Q1 2026 Earnings Call - Capital Deployment Stalls as REO Resolution Drives Book Value Decline
Lument Finance Trust reported a modest GAAP net loss of $0.02 per share in Q1 2026, driven by $1.3 million in unrealized impairments on REO assets and a $1.2 million loss on debt extinguishment. Distr...
- GAAP net loss of $0.02 per share, distributable earnings of $0.02 per share; dividend held at $0.04.
- Net interest income rose to $5.7 million, up from $5.4 million in Q4, aided by lower cost of funds.
- Weighted average coupon on the loan portfolio declined to 709 basis points from 717 basis points.
- +7 more takeaways